The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SOPH | +14.57% | N/A | N/A | -76% |
| S&P | +18.33% | +108.18% | +15.79% | +56% |
SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $18.32M | 15.9% |
| Gross Profit | $12.27M | 13.9% |
| Gross Margin | 66.97% | -1.2% |
| Market Cap | $207.18M | -30.8% |
| Market Cap / Employee | $0.49M | 0.0% |
| Employees | 423 | -5.8% |
| Net Income | -$22.41M | -47.5% |
| EBITDA | -$16.19M | -24.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $94.82M | -10.0% |
| Accounts Receivable | $9.51M | -4.2% |
| Inventory | 6.2 | -5.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $61.33M | 123.0% |
| Short Term Debt | $2.49M | -3.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -40.92% | -7.9% |
| Return On Invested Capital | -40.39% | 14.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.45M | 1.8% |
| Operating Free Cash Flow | -$9.31M | 3.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.14 | 1.80 | 2.29 | 2.42 | 7.10% |
| Price to Sales | 3.76 | 3.14 | 3.30 | 2.99 | -35.58% |
| Price to Tangible Book Value | 2.92 | 2.45 | 3.28 | 3.72 | 32.07% |
| Enterprise Value to EBITDA | -13.51 | -10.11 | -13.35 | -10.98 | -37.09% |
| Return on Equity | -52.5% | -50.4% | -60.8% | -74.1% | 62.60% |
| Total Debt | $31.67M | $30.03M | $30.13M | $63.81M | 112.21% |
SOPH earnings call for the period ending June 30, 2022.
SOPH earnings call for the period ending March 31, 2022.
SOPH earnings call for the period ending December 31, 2021.
SOPH earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
